Workflow
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
Globenewswire· 2025-12-17 13:00
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces recent advances to the CertainT-1 trial that is focused on patients with acute myeloid leukemia (AML). Following completion of the ...
SAGA Metals Defines Key Structural Geology at Trapper South & Provides Corporate Update
Globenewswire· 2025-12-17 13:00
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company advancing critical mineral discoveries, is pleased to announce the full logging of all eight drill holes completed in the Trapper zone and confirms shipping three additional holes to IGS’s lab for analysis. Additionally, important new structural data in Trapper South’s R-0014 have been identified, providing valuable insights i ...
International Energy Partner Invests $5 Million in Canada’s Energy Future
Globenewswire· 2025-12-17 13:00
The $5 million investment into MAX Power from a leading conglomerate in Vietnam has officially closed and launches an international collaboration focused on accelerating Natural Hydrogen development in Saskatchewan, positioning Canada at the forefront of a new clean energy frontier. Video: Lawson – Canada’s First Big Step into Natural Hydrogen https://www.youtube.com/watch?v=lTTOwMxz_zo SASKATOON, Saskatchewan, Dec. 17, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) ...
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
Globenewswire· 2025-12-17 13:00
ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. T ...
SharpLink Appoints Joseph Chalom as Sole CEO and Member of the Board; Rob Phythian Steps Down Following Company's Planned Transition
Globenewswire· 2025-12-17 13:00
Minneapolis, MN, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world’s largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today announced that effective December 15, 2025 its Board of Directors has appointed Joseph Chalom as sole Chief Executive Officer and elected him to the Board. Rob Phythian has stepped down from his roles as Co-Chief Executive Officer and Director, marking the completion o ...
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
Globenewswire· 2025-12-17 13:00
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in C ...
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
Globenewswire· 2025-12-17 13:00
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable market for Lifeward MARLBOROUGH, Mass., YOKNEAM ILLIT,  ...
Gabelli Funds Now Offers Seven Fully Transparent ETF Strategies
Globenewswire· 2025-12-17 13:00
GREENWICH, Conn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Gabelli Funds, LLC (“Gabelli”) today announced that all its actively managed ETFs are now fully transparent. These Gabelli ETFs complement the firm’s long-standing investment offerings across mutual funds, closed-end funds, and separate accounts – providing additional ways for advisors and investors to access Gabelli’s fundamental, bottom-up research across a range of equity and income approaches. Effective today, Gabelli offers the following seven fully t ...
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globenewswire· 2025-12-17 13:00
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14th, 2026, at 9:00 a.m. PT. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of ...
HUB Cyber Security (Nasdaq: HUBC) Announces First Half 2025 Results and Declares Its Strategic Mission: Build the Global Trust Infrastructure for the Digital Economy
Globenewswire· 2025-12-17 13:00
TEL AVIV, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”) today announced selected financial results for the six-month period ended June 30, 2025, and outlined the Company’s accelerated strategy to become the global trust infrastructure for identity, secure data, and regulated AI across industries and national ecosystems. The Company will announce the timing of its business update call in due course. The results reflect meaningful progress in strengt ...